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BACKGROUND: Cancer stem cells (CSCs) eradication might serve as a robust approach for cancer eradication. MCF-7 as breast cancer 
continuous cell line is known to contain breast CSCs 
(BCSCs) for its capability to maintain its original tumor 
population. CSCs enriched culture is a fundamental 
tool for CSCs targeted therapy development. Effective 
and unsophisticated CSCs dedifferentiation protocol for 
producing CSCs enriched culture is needed.
METHODS: MCF-7 cells were cultured initially in 
Dulbecco's  Modified  Eagle  Medium  (DMEM)  low glucose 
medium then changed to DMEM:F12. Serum starvation 
was  performed  during  each  medium  refreshment 
gradually with fetal bovine serum (FBS) concentration 
of 10%, 5%, 2.5% until reaching 1% FBS concentration. 
Stable MCF-7 culture was then adapted to serum free 
culture  system,  containing  DMEM:F12,  epidermal 
growth factor (EGF), basic fibroblast growth factor (bFGF), 
and B27 supplement as dedifferentiation protocol for 18 
days. Cluster of differentiation (CD)44 and CD24 double 
staining immunocytochemistry was performed to evaluate 
cell stemness. 
RESULTS: The population of cells expressing BCSCs 
markers (CD44+/CD24low) in non-adherent single cells 
subpopulation was significantly increased after the 
dedifferentiation procedure (70.39%) compared to control 
groups (0.71%) (p<0.05). In contrast, the expression of 
BCSCs marker in adherent single cells subpopulation and 
for both adherent and non-adherent mammosphere the 
BCSCs markers showed a stable expression.
CONCLUSION: BCSCs enrichment of breast cancer 
cell cultures from MCF-7 breast cancer cell line can 
be performed. Breast cancer cell plasticity is observed 
during the dedifferentiation protocol. Development of 
dedifferentiation inducing protocols can serve as an 
important foundation for breast cancer therapy development 
through BCSCs elimination.
KEYWORDS:  breast neoplasms, cell line, dedifferentiation, 
immunohistochemistry, neoplastic stem cells
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Introduction
Breast cancer is still the highest incident of malignancy 
among female which encompasses 24.2% of all female 
cancer and is responsible for 15% of mortality rate 
worldwide.(1) The world burden of cancer is also estimated 
to increase annually.(2) Breast cancer therapeutic strategy 
such as surgery, chemotherapy, and radiotherapy are well 
known for their curative ability, but the risk of relapse 
still exists.(3) Current cancer therapy mainly focuses on 
achieving remission status, however cancer could covertly 
progress, resulting in relapse.(4) Relapsed cancers often 
progress rapidly and have a worse prognosis.(5) Recent 
findings suggest that cancer stem cells (CSCs) play an 
important role in cancer relapse.(6)
 CSCs is a distinct tumor cell type which exhibit 
stem cells-like phenotype.(7) CSCs possess the ability to 
self-renew and differentiate, leading to the formation of 
a heterogeneous cancer cell population.(8) CSCs are also 
resistant to chemotherapy and radiotherapy, resembling 
normal stem cells.(9) Targeting CSCs could potentially 
end the prolonged war against cancer.(10) CSCs are known 
to exist in both solid and non-solid cancers, it was first 
identified in acute myeloid leukemia (AML) (11) and then 
in solid tumor (12). The most reliable method of identifying 
CSCs are by assessing their tumorigenic properties through 
inoculation into immunocompromised animals, yet the 
usage of animal models have several disadvantages.(13) 
Therefore studies on identification of CSCs biomolecular 
markers were conducted, which eventually yielded a 
particular marker expressed by CSCs.(14) CSCs marker 
differ in each cancer source, cluster of differentiation 
(CD)44, CD24, and aldehyde dehydrogenase 1 (ALDH1) 
are expressed in breast cancers, whereas CD34 and CD38 
are expressed in AML.(11,12,15) Understanding the 
biology of CSCs is important for developing an eradication 
strategy. In recent developments, CSCs studies have shown 
that asymmetric mitosis and cell dedifferentiation have a 
pivotal role in maintaining the pool of CSCs and cancer 
hierarchical population composition.
 The concept of dedifferentiation is the ability to 
reverse the cellular clock.(16) This concept was proven by 
the production of induced pluripotent stem cells (iPSCs). 
iPSCs are differentiated cells which were reprogrammed by 
induction with several growth factors (Oct4, Sox2, Klf4, 
and c-Myc).(17) In this study, terminally differentiated 
fibroblasts were able to revert back to their pluripotent 
state, an ability originally only possessed by embryonic 
stem cells (ESC).(18) Pluripotency of both iPSCs and ESC 
grant these cells the capability to differentiate into any 
type of cell which construct the body.(19) Pluripotent cells 
will undergo the differentiation process and transform into 
specific stem cells with less differentiation capaability or 
multipotent stem cells (MSC).(20) MSC could differentiate 
into specific ectoderm, mesoderm, or endoderm cell types.
(20) Oligopotent stem cells from MSC lineage have more 
limited differentiation potential and eventually produce 
specific mature unipotent stem cells which only have the 
ability to produce specific differentiated cells.(13) For 
instance, neural progenitor cells only have the ability to 
produce neuronal cells and are unable to produce cells of a 
blood cell lineage.(20) Terminally differentiated cells then 
undergo the processes of a normal cell and will eventually 
suffer from cell aging and cell death.
 The stem cell population pool is maintained by 
asymmetric mitosis, which differs from regular mitosis 
because it produces two non-identical daughter cells, stem 
cells with original stemness ability (self-renewing stem 
cells) and stem cells with limited differentiation ability.(21) 
Asymmetric mitosis, differentiation, and dedifferentiation 
mechanism also present in CSCs.(22).
 Established continuous cell lines are one example 
of a platform for in vitro studies involving cancer biology. 
Cancer cell line immortality and its ability to overcome 
the Hayflick limit (23), which limits cell division ability 
are consistent with the concept of CSCs (7), based on 
this fact it is concluded that CSCs are present among the 
cancer cell population. One of the breast cancer cell line 
is MCF-7, which originated from luminal-A breast cancer.
(24) Dedifferentiation of cancer cell lines by growth factors 
administration in growth factors supplemented serum free 
condition may produce CSC-enriched cultures that will 
serve as a basis for understanding CSC biology and the 
development of CSC targeted therapy.
Methods
This study had been approved by the Health Research 
Ethic Committee of Faculty of Medicine, Universitas 
Airlangga , Surabaya (Ethical Clearance No. 48/EC/KEPK/
FKUA/2018).
Cell Culture
MCF-7 (ATCC) human breast cancer continuous cell lines 
were obtained from the Cancer Chemopreventive Research 
Center, Universitas Gadjah Mada Yogyakarta, Indonesia. 
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MCF-7 cells were maintained in Dulbecco's  Modified  Eagle 
Medium (DMEM) low glucose medium (Gibco, New York, 
USA) with 10% fetal bovine serum (FBS) (Gibco) at 37°C, 
in a 5% CO2 saturated humidified cell culture incubator.
Serum Starvation Procedure
Confluent MCF-7 cells were passaged and the initial 
medium was replaced with DMEM:F12 (Gibco) with 10% 
FBS. Confluent cultures were passaged and prepared to 
undergo serum starvation. Serum starvation was performed 
by refreshing the culture medium every three days, with 
serum concentration of 10%, 5%, 2.5%, and 1% before 
underwent dedifferentiation process with dedifferentiation 
medium. MCF-7 serum starved cells were cultured until up 
to 80% confluence and cultured into two 24-well culture 
plate with sterile coverslips. The cells were divided into 7 
groups, which consist of 1 control group and 6 groups for 
the harvesting in the 3th, 6th, 9th, 12th, 15th, and 18th day as a 
treatment group. Each group was quadruplicated (n=4). 
BCSCs Dedifferentiation Process
Treatment group which previously cultured on DMEM:F12 
with 1% FBS then underwent medium change to 
dedifferentiation serum free medium, which composed of 
serum free DMEM:F12, human epidermal growth factors 
(EGF) (Biolegend, San Diego, California, USA), human 
basic fibroblast growth factor (bFGF) (Biolegend), and B27 
supplemented medium (Gibco).(25) The dedifferentiation 
process was carried out for 18 days, with dedifferentiation 
medium being changed every 3 days. During medium 
refreshment, morphological observations were done using 
an inverted microscope (Olympus, Tokyo, Japan). Due to the 
emergence of adherent and non-adherent cells population, 
the methods of cells retrieved were different. Adherent 
cells were directly harvested from the coverslip and fixated 
with 10% neutral buffer formalin (Merck, Kenilworth, New 
Jersey, USA). Non-adherent cells were collected from the 
culture medium, centrifuged fixated with 10% neutral buffer 
formalin (Merck), recentrifuged and retrieved from the 
pellet. Cells were collected and fixated for the control group 
on the 0th days and on the 3th, 6th, 9th, 12th, 15th, and 18th  day 
for the treatment group (n=4). 
Breast Cancer Stem Cell Marker Detection
Adherent cells were prepared by sticking coverslips 
with its adherent cells on glass slides. Non-adherent 
cells, which originated from centrifuged medium pellets 
were fixated and smeared on poly-L-lysine coated glass 
slides (Muto Pure Chemicals, Tokyo, Japan), and dried 
in a biosafety cabinet overnight. The fixated cells then 
undergo cell permeabilization which was carried out by 
incubation with 0.02% IGEPAL CA-630 (Sigma-Aldrich, 
St. Louis, Missouri, USA) for 7 minutes before the 
immunocytochemistry staining procedure was performed.
(26) CD44 and CD24 double stain immunocytochemistry 
were performed using anti-human CD44 monoclonal 
antibody (ABCAM, Cambridge, UK), anti-human CD24 
monoclonal antibody (ABCAM), and Lab Vision™ 
MultiVision Polymer Detection System double staining kit 
(ThermoFisher Scientific, Waltham, Massachusetts, USA).
 Double stain immunocytochemistry staining was 
performed according to the kit manufacturer’s protocol. 
After permeabilization protocols the blocking process was 
carried out. Blocking solution, which was Ultra V Block 
and Lab Vision™ Hydrogen Peroxidase Block which 
included in Lab Vision™ MultiVision Polymer Detection 
System kit by incubation for 5 minutes at 37°C temperature 
(ThermoFisher Scientific). Solely administration of 
MultiVision anti-rabbit/AP + anti-mouse/HRP polymer 
(cocktail) without primary antibody were used as control. 
LVRed and LVBlue Chromogen were utilized to visualized 
immunostaining for 10 minutes. Weak counterstain with 
Harris haematoxylin (Merck) was used to stain cell nuclei 
by incubating for 10 seconds. Immunocytochemistry 
stained cells were then observed under a Leica DM750 light 
microscope (Leica, Wetzlar, Germany).
Immunocytochemistry Interpretation
Expression of CD24 on the cells is represented by the 
red-brown colour of the cells, and blue colour indicates 
the expression of CD44 marker. The cells were grouped 
into two groups of observation: mammosphere and single 
cell population. Based on CD44/CD24 expression, the 
cells were divided into 5 groups (CD44-/CD24+, CD44+/
CD24low, CD44+/CD24medium, CD44+/CD24high, and CD44+/
CD24-). BCSCs quantification and the measurement of 
population percentage were utilized to evaluate the degree 
of dedifferentiation and the distribution of cell phenotype 
based on the BCSCs marker expression.(27,28) Divided 
observation of single cells and mammosphere population 
were done for both adherent and non-adherent populations 
by two independent pathologist (Figure 1, Figure 2).
Statistical Analysis
Kruskall-Wallis’s analysis with SPSS ver 24 (IBM 
Coorporation, New York, USA) was performed to evaluate 
BCSCs marker expression difference for adherent and non-
adherent cells in single cell and mammosphere populations. 
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Results
Morphological Change
Epithelial-mesenchymal transition (EMT) was the change of 
cell morphology and characteristics that occurs in epithelial 
cells. This change could cause epithelial cell phenotypes 
to change into mesenchymal cells, while the reverse 
mechanism, which changed mesenchymal cell phenotypes 
into epithelial phenotypes was called mesenchymal to 
epithelial transition (MET). Epithelial cells were usually 
present in glands and the surface of organs, which tend to 
be stationary and have a limited ability of migration. On 
the other hand, mesenchymal cell types were mainly present 
in the stroma of organs with good mobility and dynamic 
Non-adherent single cells
Adherent cells on coverslip 
Non-adherent cells on 
culture supernatant
Adherent mammosphere
Non-adherent mammosphere
Adherent single cells
Figure 1. Workflow of molecular 
marker expression interpretation.
A B C
Figure 2. Grouping of cells phenotype based on marker expression. A: CD24low/CD44+ (white arrow), CD24medium/CD44+ (red 
arrow) and CD24high/CD44+ (black arrow) cells on the 18th days of dedifferentiation; B: Haematoxylin-Eosin staining on the 18th days of 
dedifferentiation; C: CD24+/CD44- cells (green arrow) on the 12th days of dedifferentiation. Black bar: 10 mm.
adaptability. In stem cell biology, the process of EMT 
explains the activation and homing ability of stem cells. 
EMT was a dynamic process, which occurred ubiquitously 
in the organism, and a miss in EMT might result in grave 
consequences.
 The initial MCF-7 cell line morphology was 
squamous cells with hexagonal-shaped membranes could 
be observed in the control groups both in before or after 
the serum starvation procedure (Figure 3). On the 3rd day 
of dedifferentiation protocol, MCF-7 morphology gradually 
changed from squamous into a round-shaped form, 
aggregated and began to form anchored cauliflower-like 
structures (Figure 3). Dedifferentiation of MCF-7 yielded 
two different populations on the 6th day: adherent and non-
adherent populations. Mammosphere was the formation of 
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A B C
Figure 3. Squamous cell appearance, cauliflower-like morphological change, and non-adherent cells formation. A: Adherent 
squamous cells with epithelial likes phenotype MCF-7 morphology on control group (D-0); B: Adherent cauliflower-like structure, lost of 
adherence, EMT-like process on the 3th days of dedifferentiation; C: Mammospheres formation on the 18th days of dedifferentiation. White 
bar: 10 mm; Black bar: 100 mm.
A B C
D E F
Figure 4. Serial staining of cells during culture in dedifferentiation inducing medium in the adherent population. A: Adherent cells 
on the 3rd days observation; B: Adherent cells on the 6th days observation; C: Adherent cells on the 9th days observation; D: Adherent cells 
on the 12th days observation; E: Adherent cells on the 15th days observation; F: Adherent cells on the 18th days observation. CD24/CD44 
double staining, Red bar: 10 mm.
spherical structure consisted of breast cells which could 
be observed beginning in the 3rd day. Detached cells and 
mammosphere from the cauliflower-like structure gave rise 
to the non-adherent population (Figure 1, Figure 2, Figure 
3). Mammosphere growth and multiplication occurred on 
the 6th, 9th, 12th, 15th, and 18th day of the dedifferentiation 
protocol.
 Based on the MCF-7 morphological change during the 
dedifferentiation protocol, EMT like process was observed, 
especially in the first three days of the protocol. Initial 
MCF-7 squamous morphology, which was closely related 
to epithelial phenotype gradually began to changed into 
a rounder  cell  shape  and  lost  its  original  epithelial 
appearance (Figure 3, with serial labeling in Figure 4 and 
Figure 5).  This process might be closely related to the 
mechanism of metastasis, making it a vital process in cancer 
biology. This finding suggests that this dedifferentiation 
protocol might be utilized to obtain a closer look into the 
EMT process by performing a specific EMT related marker 
and assays.
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A B C
D E F
Figure 5. Serial staining of cells during culture in dedifferentiation inducing medium in the non-adherent population. A: Non-
adherent cells on the 3rd days observation; B: Non-adherent cells on the 6th days observation; C: Non-adherent cells on the 9th days 
observation; D: Non-adherent cells on the 12th days observation; E: Non-adherent cells on the 15th days observation; F: Non-adherent cells 
on the 18th days observation. CD24/CD44 double staining, Red bar: 10 mm.
CD44 and CD24 Expression Profile Difference in The 
Single Cell Population
CD24 marker was indicated by the appearance of red-
brownish colour, while CD44 marker was marked by blue 
colour. Based on the intensity of colour, intensity of CD24 
expression is graded as high, medium or low expressing 
cells, while a faint colour was only able to distinguish 
between expressing and non-expressing cells.
 Disseminated single cells of the enriched MCF-7 
CSCs culture could be detected in both the adherent and 
non-adherent cells population beginning from the 6th day 
of dedifferentiation protocol (Table 1, Table 2) The initial 
population of MCF-7 breast cancer cell lines exhibited an 
immense surface expression of CD24, yet CD44 expression 
was barely detectable. High levels of CD24 expression and 
limited expression of CD44 in the initial MCF-7 population 
suggested that it contained breast cancer cells with a high 
degree of differentiation. The initial MCF-7 monolayer 
culture was dominated with CD24+/CD44- cells, which 
showed a high degree of breast cancer differentiation. 
Detection of CD44 expression increased along the course 
of dedifferentiation protocols mainly in the non-adherent 
subpopulation (Table 2). Observation of population cell 
dynamics in the adherent population began from the 3rd 
day, with a notable gradual growth of the CD24medium/
CD44+ population and decreasing levels of CD24low/CD44+ 
population. The trend of CD24high/CD44+ cell stabilized 
during the dedifferentiation protocol and peaked on the 
12th day. This results suggest that the subpopulation of non-
adherent single cells was dominated by the  CD24low/CD44+ 
at the end of culture in dedifferentiation medium, yet the 
adherent single cells exhibit a more maturation phenotype.
Difference in CD44 and CD24 Expression Profiles in The 
Mammosphere Population
MCF-7 mammospheres from the CSC-enriched culture 
were observed in the form of non- adherent and adherent 
population. Non-adherent mammosphere were observed 
from the 6th day, and on the 12th day the adherent 
mammosphere was identified (Table 2, Figure 4, Figure 5).
 CD24 expression as a marker of breast cancer 
differentiation was prominently observed in the adherent 
mammosphere and CD44 expression as a breast cancer 
stemness marker was more prominent in the non-adherent 
mammosphere. However, compared to the non-adherent 
single cell population, the CSCs markers were less prominent 
in  the  mammosphere  population (Table 1, Table 2).
 From the 6th day, CD24medium/CD44+ cells dominated 
the non-adherent mammosphere. Conversely in the 
adherent mammosphere population, the differentiate 
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CD24high/CD44+ cells were dominating from the 12th day 
of the dedifferentiation protocol until the 18th day. The 
rising percentage of CD24low/CD44+ cells, which occurred 
in the non-adherent mammosphere in line with the 
dedifferentiation protocols duration, was observed in the 
non-adherent mammosphere populations (Table 2)
Discussion
Dedifferentiation Signaling
Cancer dedifferentiation is tightly linked with inflammation, 
hypoxia, and response to cellular damage.(29) These 
pathways of cellular dedifferentiation eventually cross in 
hypoxia-inducible factors (HIF)-1α and HIF-2α signaling. 
HIF-1α and HIF-2α are peculiar protein which are usually 
degraded in normoxic conditions, but maintained in hypoxic 
conditions.(30) HIF-1α and HIF-2α translocate into the 
nucleus, binding with HIF-1β to form a protein complex 
which goes into DNA hypoxia response element (HRE) 
and triggers transcription of complex cellular signaling 
molecules of hypoxia response and cell dedifferentiation.
(31,32)
 EGF and bFGF which are present in the inflammation 
and cellular damage response could mimic hypoxic signaling 
conditions and arrest the HIF-1α and HIF-2α degradation 
process, which eventually triggers cellular dedifferentiation.
(32–34) This method could possibly produce CSCs by 
dedifferentiating malignant cells. In the in vitro setting 
the supplementation of EGF and bFGF to the serum free 
medium could mimic this in vivo process and yield a CSC-
enriched culture.
Expression of BCSC Markers
BCSC marker detection using immunocytochemistry is one 
of the techniques able to detect the presence of CSCs in the 
heterogeneous cell line population. Expression of CD44 is 
thought to be a stemness marker whereas CD24 acts as a 
marker of differentiation in breast CSCs.(15) Utilization 
of simultaneous detection of CD24 and CD44 in double 
staining immunocytochemistry allows CD44+/CD24-/low 
cells which are thought to be BCSCs to be distinguished 
from the rest of the population. Elevated levels of CD44 
expression and low CD24 expression could determine 
the success of dedifferentiation protocols (15), yet the 
dedifferentiation protocols reveal 4 distinct subpopulation 
of cells inside MCF-7 breast cancer cell line population. The 
4 subgroups are distinguished based on cell adherence and 
cell morphology as a single cell or mammosphere forming 
population. BCSC marker expression from the 4 subgroups 
varies from each other, but the main difference is that the 
adherent population tends to express higher amounts of 
differentiation markers than the non-adherent population. 
However, the mammosphere forming subpopulation 
showed domination of CD24medium/CD44+ cells which have 
a moderate level of differentiation degree between the CSCs 
and differentiate cancer cells. These results suggest that 
the 4 distinct subpopulation of cancer cells identified in 
this study could be present in every cancer cell population, 
hinting that the theory of an existence of a lineage of cancer 
cell population from CSCs could be proven. Nevertheless, 
future studies should utilize an in vivo assay for assessing 
cell tumorigenicity to determine how these subpopulations 
differ in their ability to cause cancer. Confirmation of a 
cell’s ability to dedifferentiate and give rise to an original 
MCF-7 cells population should also be performed. Isolation 
of each respective subpopulation and culturing them in 
serum supplemented medium could be performed to assess 
the differentiation capability of each subpopulation. Further 
confirmation by other quantitative techniques such as 
flowcytometry is also encouraged.
Clinical Implication
Development of BCSC-enriched cultures from breast 
cancer continuous cell lines could serve as the platform 
for the development of CSC targeted therapy and provide 
a deeper understanding of CSC biology.(7) In the clinical 
setting, development of CSC targeted therapy, especially 
with regards  to  breast  cancer  treatment  could  hopefully 
plummet  the  number  of  relapsing  cancer  cases  and 
provide a novel approach to cancer therapy. In the future, 
CSC targeted therapy could replace the use of costly and 
hazardous cytostatic agents in current chemotherapy 
regimens as well as decreasing the potential side effects of 
radiotherapy.
Conclusion
Development of BCSC-enriched cultures from MCF-7 
breast cancer continuous cell lines could be performed 
by utilizing serum-free medium supplemented by EGF, 
bFGF and B27 supplement medium. BCSCs-enrichment 
was completed by reprogramming breast cancer cell lines 
to undergo a dedifferentiation process through hypoxia 
response related pathways.
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